Ipratropium Bromide

Research use only, not for human use.

Ipratropium Bromide is an antagonist of M3 type muscarinic acetylcholine receptors, used for the treatment of chronic obstructive pulmonary disease (COPD).

Ipratropium Bromide is an antagonist of M3 type muscarinic acetylcholine receptors, used for the treatment of chronic obstructive pulmonary disease (COPD).

Cell Viability Assay Cell Line:Adult Rat Cardiac Myocyte Concentration:0.001 nM-0.1 mM Incubation Time:2 h in dark; prior to 4 h hypoxia Result:Resulted cell viability in a dose-dependent manner, with the inhibition rate of 52.7% at 0.1 mM dose.

Animal Model:Guinea-pigs of the Dunkin Hartley strain.Dosage:0.1-1 μg/kg Administration:Intravenous injection; single dose Result:Resulted little blocking effect on post-junctional muscarinic receptors at 0.3 μg/kg, and inhibited ACh-induced bronchoconstriction at 0.5 μg/kg.Animal Model:Male Sprague-Dawley rats (300-350 g) Dosage:0.04 mg/20 mL and 0.20 mg/20 mL Administration:Inhalation; atomization rate of 30 mL/30 min; 30 min Result:Had no significant effects on any parameters recorded in healthy rats but exerted a protective effect against the inflammatory reaction elicited by cadmium.

Ipratropium Bromide

Endocrinology/Hormones

AChR

M3 mAChR

Neurological Disease

——

22254-24-6

412.37

C20H30BrNO3

>98% (HPLC)

DMSO:83 mg/mL (201.27 mM); Ethanol:83 mg/mL (201.27 mM); Water:83 mg/mL (201.27 mM)

CC([N+]1(C)C2CC(OC(C(C3=CC=CC=C3)CO)=O)CC1CC2)C.[Br-]

(endo,syn)-(±)-3-(3-Hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azoniabicyclo[3.2.1]octane bromide

(-20℃)

With Ice Pack

≥ 2 years